Skip to main content

Table 1 Descriptive characteristics of the first breast cancer among 1-year survivors of a first primary breast cancer in 12 SEER registries, 1992–2016

From: Risk of contralateral breast cancer according to first breast cancer characteristics among women in the USA, 1992–2016

  

Calendar period of first breast cancer diagnosis

 

Overall

1992–1997

1998–2003

2004–2009

2010–2015

Characteristics of the first breast cancer

N = 419,818

N = 89,052

N = 107,103

N = 107,828

N = 115,835

Overall, %

100.0

21.2

25.5

25.7

27.6

Year of diagnosis, mean years (SD)

2004.0 (6.8)

1994.6 (1.7)

2000.5 (1.7)

2006.5 (1.7)

2012.5 (1.7)

Age at diagnosis, years, %

 < 40

5.9

6.7

6.1

5.8

5.3

 40 to < 50

20.4

20.7

20.8

21.4

18.8

 50 to < 60

26.1

23.0

26.7

27.5

26.6

 60 to < 70

24.3

23.4

21.9

23.6

27.9

 ≥ 70

23.3

26.2

24.6

21.7

21.4

Age at diagnosis, mean years (SD)

58.8 (12.7)

59.2 (13.1)

58.8 (12.9)

58.4 (12.6)

59.0 (12.2)

Stage at diagnosis, %

 I

50.7

50.9

50.9

50.2

50.7

 II

36.0

33.8

35.4

36.7

37.7

 III

13.3

15.4

13.7

13.1

11.6

Histology, %

 Ductal

75.4

73.4

72.3

76.3

79.1

 Lobular

8.3

7.7

8.1

8.1

9.3

 Mixed

7.1

5.7

9.1

7.8

5.6

 Other

9.2

13.3

10.5

7.8

6.1

ER status, %

 Positive

73.1

62.0

68.6

76.4

82.8

 Negative

18.6

20.2

18.6

19.8

16.0

 Borderline/unknown

8.3

17.7

12.8

3.7

1.2

Initial treatment receipt, %

 Surgerya

  None

2.0

1.2

1.7

3.1

  BCS/unilateral mastectomy

87.9

91.3

89.5

83.4

  Contralateral prophylactic mastectomy

7.3

2.9

6.8

11.8

  Unknown

2.8

4.6

2.0

1.7

 Radiation therapy

  Yes

54.2

45.0

55.3

56.8

58.0

  No/unknown

45.8

55.1

44.7

43.2

42.1

 Chemotherapy

  Yes

40.5

31.3

41.9

45.0

42.0

  No/unknown

59.5

68.8

58.1

55.0

58.0

 Hormone therapy

  Yes

42.9

32.5

37.4

43.2

55.6

  No/unknown

57.1

67.5

62.6

56.8

44.4

HER2 statusb, %

 Positive

14.5

14.5

 Negative

80.6

80.6

 Borderline/unknown

4.9

4.9

Breast cancer subtypeb,c, %

 HR+/HER2+

10.2

10.2

 HR+/HER2−

70.3

70.3

 HR−/HER2+

4.3

4.3

 HR−/HER2− (Triple negative)

10.2

10.2

 Unknown

5.0

5.0

  1. SEER, Surveillance, Epidemiology, and End Results; ER, estrogen receptor; BCS, breast conserving surgery; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; PR, progesterone receptor
  2. aInformation on initial surgery was available for breast cancers diagnosed from 1998+ (N = 330,766)
  3. bHER2 status was routinely collected in 2010+. Estimates include first breast cancers diagnosed from 2010 to 2015 and followed through 2016 (N = 115,835)
  4. cHR+ = ER+ and/or PR+; HR− = ER− and PR−